Document Detail


Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery.
MedLine Citation:
PMID:  15556966     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cardiac preconditioning is thought to be involved in the observed decreased coronary artery reocclusion rate in patients with angina preceding myocardial infarction. We prospectively examined whether preconditioning by sevoflurane would decrease late cardiac events in patients undergoing coronary artery bypass graft (CABG) surgery. METHODS: Seventy-two patients scheduled for elective CABG surgery were randomized to preconditioning by sevoflurane (10 min at 4 vol%) or placebo. For all patients, follow-up of adverse cardiac events was obtained 6 and 12 months after surgery. Transcript levels for platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31), catalase and heat shock protein 70 (Hsp70) were determined in atrial biopsies after sevoflurane preconditioning. RESULTS: Pharmacological preconditioning by sevoflurane reduced the incidence of late cardiac events during the first year after CABG surgery (sevoflurane 3% vs 17% in the placebo group, log-rank test, P=0.038). One patient in the sevoflurane group and three patients in the placebo group experienced new episodes of congestive heart failure and three additional patients had coronary artery reocclusion. Perioperative peak concentrations for myocardial injury markers were higher in patients with subsequent late cardiac events [NTproBNP, 9031 (4125) vs 3049 (1906) ng litre(-1), P<0.001; cTnT, 1.31 (0.88) vs 0.46 (0.29) microg litre(-1), P<0.001]. Transcript levels were reduced for PECAM-1 and increased for catalase but unchanged for Hsp70 in atrial biopsies after sevoflurane preconditioning. CONCLUSIONS: This prospective randomized clinical study provides evidence of a protective role for pharmacological preconditioning by sevoflurane in late cardiac events in CABG patients, which may be related to favourable transcriptional changes in pro- and antiprotective proteins.
Authors:
C Garcia; K Julier; L Bestmann; A Zollinger; L K von Segesser; T Pasch; D R Spahn; M Zaugg
Related Documents :
18319356 - Atrial natriuretic peptide protects against ischemia-reperfusion injury in rabbit heart...
1415616 - Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated r...
8997336 - Katp channels mediate late preconditioning against infarction produced by monophosphory...
8651046 - Cardiovascular and autonomic effects of sevoflurane.
16946446 - Acute therapy of maternal and fetal arrhythmias during pregnancy.
21752036 - Intra-aortic balloon counterpulsation 50 years later: initial conception and consequent...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2004-11-19
Journal Detail:
Title:  British journal of anaesthesia     Volume:  94     ISSN:  0007-0912     ISO Abbreviation:  Br J Anaesth     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-01-04     Completed Date:  2005-03-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372541     Medline TA:  Br J Anaesth     Country:  England    
Other Details:
Languages:  eng     Pagination:  159-65     Citation Subset:  IM    
Affiliation:
Institute of Anesthesiology, University Hospital Zurich, Zurich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anesthetics, Inhalation / therapeutic use*
Antigens, CD31 / blood*
Cardiotonic Agents / therapeutic use
Coronary Artery Bypass*
Disease-Free Survival
Female
Heart Diseases / prevention & control
Humans
Ischemic Preconditioning, Myocardial / methods*
Male
Methyl Ethers / therapeutic use*
Middle Aged
Postoperative Complications / prevention & control
Prospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anesthetics, Inhalation; 0/Antigens, CD31; 0/Cardiotonic Agents; 0/Methyl Ethers; 28523-86-6/sevoflurane

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of halothane, sevoflurane and propofol on left ventricular diastolic function in humans duri...
Next Document:  Release of tumour necrosis factor alpha (TNFalpha) by TNFalpha cleaving enzyme (TACE) in response to...